Hims & Hers (NASDAQ: HIMS) stock has done well since the company went public a few years ago. It has soared by over 193% in ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filling in the gaps.

Online pharmacies are where it’s at—places like Hims, HenryMeds, and a bunch of others that ... They’ve expanded from treating erectile dysfunction and hair loss to offering weight loss solutions, ...

Bloomberg / Contributor / Getty Images Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration (FDA) said Eli Lilly's popular weight-loss drugs are no longer on its list ...

A hernia happens when an internal organ or other tissue pushes through the connective tissue or muscle that normally contains ...

All that a commodity means is that Hims would not get a premium on its GLP1 offering. Instead, it will sell GLP1 drugs with a small margin. But this consideration seemingly avoids the massive ...

Also Read: Hims & Hers To Offer Access To Compounded Diabetes And Weight Loss Drugs For Just $99/Month To Certain Professional Personnel. Many people opting for compounded GLP-1s cite lower costs ...

Shares of Hims & Hers Health fell almost 10% today following an announcement from the U.S. Food and Drug Administration (FDA) that competitor Eli Lilly’s obesity and diabetes drugs are no longer ...

HIMS & HERS HEALTH INC (HIMS) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s ...

NEW YORK, Oct. 4, 2024 /PRNewswire/ -- Hims & Hers Health, Inc. (NYSE:HIMS) will replace Vector Group Ltd (NYSE:VGR) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday ...